From concept to reality: The long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 221-229

  Dussault, Isabelle ^a   Bellon, Steven F ^a,b  

^a AMGEN INC   (United States)

^b Department of Structural Biology   (United States)

Author keywords

C Met; Cancer; Crystal structure; Kinase inhibitor; RON; Small molecule

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AM 7; ARQ 197; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN RON; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; RON PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CRYSTAL STRUCTURE; DOWN REGULATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; PATENT; PHARMACOLOGICAL BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 64049101039     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787313792     Document Type: Review

References (87)

1. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 2003, 4(12), 915-925.
2. Borowiak, M.; Garratt, A.N.; Wustefeld, T.; Strehle, M.; Trautwein, C.; Birchmeier, C. Met provides essential signals for liver regeneration. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10608-10613.
3. Huh, C.G.; Factor, V.M.; Sanchez, A.; Uchida, K.; Conner, E.A.; Thorgeirsson, S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA, 2004, 101(13), 4477-4482.
4. McKinnon, H.; Gherardi, E.; Reidy, M.; Bowyer, D. Hepatocyte growth factor/scatter factor and MET are involved in arterial repair and atherogenesis. Am. J. Pathol., 2006, 168(1), 340-348.
5. Douglas, D.; Chen, G.; Khalil, N. Increase in the beta chain of hepatocyte growth factor (HGF beta) precedes c-met expression after bleomycin-induced lung injury in the rat. Exp. Lung Res., 2002, 28(4), 301-314.
6. Hashimoto, N.; Yamanaka, H.; Fukuoka, T.; Dai, Y.; Obata, K.; Mashimo, T.; Noguchi, K. Expression of HGF and cMet in the peripheral nervous system of adult rats following sciatic nerve injury. Neuroreport, 2001, 12(7), 1403-1407.
7. Ueda, H.; Sawa, Y.; Matsumoto, K.; Kitagawa-Sakakida, S.; Kawahira, Y.; Nakamura, T.; Kaneda, Y.; Matsuda, H. Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann. Thorac. Surg., 1999, 67(6), 1726-1731.
8. Beilmann, M.; Odenthal, M.; Jung, W.; Vande Woude, G.F.; Dienes, H.P.; Schirmacher, P. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood, 1997, 90(11), 4450-4458.
9. Fausto, N. Hepatocyte growth factor receptor and the c-met oncogene. Hepatology, 1991, 14(4 Pt 1), 738-740.
10. Chmielowiec, J.; Borowiak, M.; Morkel, M.; Stradal, T.; Munz, B.; Werner, S.; Wehland, J.; Birchmeier, C.; Birchmeier, W. c-Met is essential for wound healing in the skin. J. Cell Biol., 2007, 177(1), 151-162.
11. Yoshida, S.; Yamaguchi, Y.; Itami, S.; Yoshikawa, K.; Tabata, Y.; Matsumoto, K.; Nakamura, T. Neutralization of hepatocyte growth factor leads to retarded cutaneous wound healing associated with decreased neovascularization and granulation tissue formation. J. Invest. Dermatol., 2003, 120(2), 335-343.
12. Ronsin, C.; Muscatelli, F.; Mattei, M.G.; Breathnach, R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene, 1993, 8(5), 1195-1202.
13. Gaudino, G.; Avantaggiato, V.; Follenzi, A.; Acampora, D.; Simeone, A.; Comoglio, P.M. The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene, 1995, 11(12), 2627-2637.
14. Leonis, M.A.; Toney-Earley, K.; Degen, S.J.; Waltz, S.E. Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure. Hepatology, 2002, 36(5), 1053-1060.
15. Waltz, S.E.; Eaton, L.; Toney-Earley, K.; Hess, K.A.; Peace, B.E.; Ihlendorf, J.R.; Wang, M.H.; Kaestner, K.H.; Degen, S.J. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J. Clin. Invest., 2001, 108(4), 567-576.
16. Gaudino, G.; Follenzi, A.; Naldini, L.; Collesi, C.; Santoro, M.; Gallo, K.A.; Godowski, P.J.; Comoglio, P.M. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J., 1994, 13(15), 3524-3532.
17. Wang, M.H.; Ronsin, C.; Gesnel, M.C.; Coupey, L.; Skeel, A.; Leonard, E.J.; Breathnach, R. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science, 1994, 266(5182), 117-119.
18. Bottaro, D.P.; Rubin, J.S.; Faletto, D.L.; Chan, A.M.; Kmiecik, T.E.; Vande Woude, G.F.; Aaronson, S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science, 1991, 251(4995), 802-804.
19. Medico, E.; Mongiovi, A.M.; Huff, J.; Jelinek, M.A.; Follenzi, A.; Gaudino, G.; Parsons, J.T.; Comoglio, P.M. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol. Biol. Cell, 1996, 7(4), 495-504.
20. Ponzetto, C.; Bardelli, A.; Zhen, Z.; Maina, F.; dalla Zonca, P.; Giordano, S.; Graziani, A.; Panayotou, G.; Comoglio, P.M. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell, 1994, 77(2), 261-271.
21. Danilkovitch-Miagkova, A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr. Cancer Drug Targets, 2003, 3(1), 31-40.
22. Chen, Y.Q.; Zhou, Y.Q.; Fisher, J.H.; Wang, M.H. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene, 2002, 21(41), 6382-6386.
23. Santoro, M.M.; Penengo, L.; Minetto, M.; Orecchia, S.; Cilli, M.; Gaudino, G. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene, 1998, 17(6), 741-749.
24. Zhou, Y.Q.; Chen, Y.Q.; Fisher, J.H.; Wang, M.H. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages. J. Biol. Chem., 2002, 277(41), 38104-38110.
25. Zhou, Y.Q.; He, C.; Chen, Y.Q.; Wang, D.; Wang, M.H. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene, 2003, 22(2), 186-197.
26. Peace, B.E.; Hughes, M.J.; Degen, S.J.; Waltz, S.E. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene, 2001, 20(43), 6142-6151.
27. Peace, B.E.; Toney-Earley, K.; Collins, M.H.; Waltz, S.E. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res., 2005, 65(4), 1285-1293.
28. Jeffers, M.; Fiscella, M.; Webb, C.P.; Anver, M.; Koochekpour, S.; Vande Woude, G.F. The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl. Acad. Sci. USA, 1998, 95(24), 14417-14422.
29. Jeffers, M.; Rong, S.; Anver, M.; Vande Woude, G.F. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. Oncogene, 1996, 13(4), 853-856.
30. Jeffers, M.F. Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling. Oncogene, 1999, 18(36), 5120-5125.
31. Park, M.; Dean, M.; Cooper, C.S.; Schmidt, M.; O'Brien, S.J.; Blair, D.G.; Vande Woude, G.F. Mechanism of met oncogene activation. Cell, 1986, 45(6), 895-904.
32. Soman, N.R.; Correa, P.; Ruiz, B.A.; Wogan, G.N. The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc. Natl. Acad. Sci. USA, 1991, 88(11), 4892-4896.
33. Yu, J.; Miehlke, S.; Ebert, M.P.; Hoffmann, J.; Breidert, M.; Alpen, B.; Starzynska, T.; Stolte Prof, M.; Malfertheiner, P.; Bayerdorffer, E. Frequency of TPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives. Cancer, 2000, 88(8), 1801-1806.
34. Heideman, D.A.; Snijders, P.J.; Bloemena, E.; Meijer, C.J.; Offerhaus, G.J.; Meuwissen, S.G.; Gerritsen, W.R.; Craanen, M.E. Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma. J. Pathol., 2001, 194(4), 428-435.
35. Zinser, G.M.; Leonis, M.A.; Toney, K.; Pathrose, P.; Thobe, M.; Kader, S.A.; Peace, B.E.; Beauman, S.R.; Collins, M.H.; Waltz, S.E. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res., 2006, 66(24), 11967-11974.
36. Cheburkin Iu, V.; Kniazeva, T.G.; Peter, S.; Kniazev Iu, P.; Karelin, M.I.; Shkol'nik, M.I.; Evtushenko, V.I.; Hanson, K.P.; Ullrich, A.; Kniazev, P.G. [Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells]. Mol. Biol. (Mosk)., 2002, 36(3), 480-490.
37. Jeffers, M.; Schmidt, L.; Nakaigawa, N.; Webb, C.P.; Weirich, G.; Kishida, T.; Zbar, B.; Vande Woude, G.F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA, 1997, 94(21), 11445-11450.
38. Graveel, C.; Su, Y.; Koeman, J.; Wang, L.M.; Tessarollo, L.; Fiscella, M.; Birchmeier, C.; Swiatek, P.; Bronson, R.; Vande Woude, G. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc. Natl. Acad. Sci. USA, 2004, 101(49), 17198-17203.
39. Dussault I, K.-L. P., Jun HT, Coxon A, Burgess TL HGF- and c-Met-targeted drugs: hopes, challenges and their future in cancer therapy. Drugs Future, 2006, 31(9), 819-825.
40. Xu, X.M.; Wang, D.; Shen, Q.; Chen, Y.Q.; Wang, M.H. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene, 2004, 23(52), 8464-8474.
41. O'Toole, J.M.; Rabenau, K.E.; Burns, K.; Lu, D.; Mangalampalli, V.; Balderes, P.; Covino, N.; Bassi, R.; Prewett, M.; Gottfredsen, K.J.; Thobe, M.N.; Cheng, Y.; Li, Y.; Hicklin, D.J.; Zhu, Z.; Waltz, S.E.; Hayman, M.J.; Ludwig, D.L.; Pereira, D.S. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res., 2006, 66(18), 9162-9170.
42. Schmidt, L.; Duh, F.M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S.W.; Zhuang, Z.; Lubensky, I.; Dean, M.; Allikmets, R.; Chidambaram, A.; Bergerheim, U.R.; Feltis, J.T.; Casadevall, C.; Zamarron, A.; Bernues, M.; Richard, S.; Lips, C.J.; Walther, M.M.; Tsui, L.C.; Geil, L.; Orcutt, M.L.; Stackhouse, T.; Lipan, J.; Slife, L.; Brauch, H.; Decker, J.; Niehans, G.; Hughson, M.D.; Moch, H.; Storkel, S.; Lerman, M.I.; Linehan, W.M.; Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet., 1997, 16(1), 68-73.
43. Zhuang, Z.; Park, W.S.; Pack, S.; Schmidt, L.; Vortmeyer, A.O.; Pak, E.; Pham, T.; Weil, R.J.; Candidus, S.; Lubensky, I.A.; Linehan, W.M.; Zbar, B.; Weirich, G. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat. Genet., 1998, 20(1), 66-69.
44. Di Renzo, M.F.; Olivero, M.; Martone, T.; Maffe, A.; Maggiora, P.; Stefani, A.D.; Valente, G.; Giordano, S.; Cortesina, G.; Comoglio, P.M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 2000, 19(12), 1547-1555.
45. Kuniyasu, H.; Yasui, W.; Kitadai, Y.; Yokozaki, H.; Ito, H.; Tahara, E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun., 1992, 189(1), 227-232.
46. Sakakura, C.; Mori, T.; Sakabe, T.; Ariyama, Y.; Shinomiya, T.; Date, K.; Hagiwara, A.; Yamaguchi, T.; Takahashi, T.; Nakamura, Y.; Abe, T.; Inazawa, J. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer, 1999, 24(4), 299-305.
47. Nessling, M.; Solinas-Toldo, S.; Wilgenbus, K.K.; Borchard, F.; Lichter, P. Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer, 1998, 23(4), 307-316.
48. Di Renzo, M.F.; Olivero, M.; Giacomini, A.; Porte, H.; Chastre, E.; Mirossay, L.; Nordlinger, B.; Bretti, S.; Bottardi, S.; Giordano, S.; Plebani, M.; Gespach, C.; Comoglio, P.M. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res., 1995, 1(2), 147-154.
49. Moore, S.R.; Persons, D.L.; Sosman, J.A.; Bobadilla, D.; Bedell, V.; Smith, D.D.; Wolman, S.R.; Tuthill, R.J.; Moon, J.; Sondak, V.K.; Slovak, M.L. Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence In situ Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431). Clin. Cancer Res., 2008, 14(10), 2927-2935.
50. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Janne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827), 1039-1043.
51. Bean, J.; Brennan, C.; Shih, J.Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.C.; Yu, C.J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.F.; Yang, P.C.; Miller, V.; Ladanyi, M.; Yang, C.H.; Pao, W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. USA, 2007, 104(52), 20932-20937.
52. Smolen, G.A.; Sordella, R.; Muir, B.; Mohapatra, G.; Barmettler, A.; Archibald, H.; Kim, W.J.; Okimoto, R.A.; Bell, D.W.; Sgroi, D.C.; Christensen, J.G.; Settleman, J.; Haber, D.A. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA, 2006, 103(7), 2316-2321.
53. Wang, M.H.; Lee, W.; Luo, Y.L.; Weis, M.T.; Yao, H.P. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J. Pathol., 2007, 213(4), 402-411.
54. Thomas, R.M.; Toney, K.; Fenoglio-Preiser, C.; Revelo-Penafiel, M.P.; Hingorani, S.R.; Tuveson, D.A.; Waltz, S.E.; Lowy, A.M. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res., 2007, 67(13), 6075-6082.
55. Maggiora, P.; Marchio, S.; Stella, M.C.; Giai, M.; Belfiore, A.; De Bortoli, M.; Di Renzo, M.F.; Costantino, A.; Sismondi, P.; Comoglio, P.M. Overexpression of the RON gene in human breast carcinoma. Oncogene, 1998, 16(22), 2927-2933.
56. Angeloni, D.; Danilkovitch-Miagkova, A.; Ivanova, T.; Braga, E.; Zabarovsky, E.; Lerman, M.I. Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter. Oncogene, 2007, 26(31), 4499-4512.
57. Collesi, C.; Santoro, M.M.; Gaudino, G.; Comoglio, P.M. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol. Cell Biol., 1996, 16(10), 5518-5526.
58. Camp, E.R.; Yang, A.; Gray, M.J.; Fan, F.; Hamilton, S.R.; Evans, D.B.; Hooper, A.T.; Pereira, D.S.; Hicklin, D.J.; Ellis, L.M. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer, 2007, 109(6), 1030-1039.
59. Bonine-Summers, A.R.; Aakre, M.E.; Brown, K.A.; Arteaga, C.L.; Pietenpol, J.A.; Moses, H.L.; Cheng, N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol. Ther., 2007, 6(4), 561-570.
60. Scheving, L.A.; Stevenson, M.C.; Taylormoore, J.M.; Traxler, P.; Russell, W.E. Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation. Biochem. Biophys. Res. Commun., 2002, 290(1), 197-203.
61. Jo, M.; Stolz, D.B.; Esplen, J.E.; Dorko, K.; Michalopoulos, G.K.; Strom, S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem., 2000, 275(12), 8806-8811.
62. Presnell, S.C.; Stolz, D.B.; Mars, W.M.; Jo, M.; Michalopoulos, G.K.; Strom, S.C. Modifications of the hepatocyte growth factor/c-met pathway by constitutive expression of transforming growth factor-alpha in rat liver epithelial cells. Mol. Carcinog., 1997, 18(4), 244-255.
63. Huang, P.H.; Mukasa, A.; Bonavia, R.; Flynn, R.A.; Brewer, Z.E.; Cavenee, W.K.; Furnari, F.B.; White, F.M. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. USA, 2007, 104(31), 12867-12872.
64. Follenzi, A.; Bakovic, S.; Gual, P.; Stella, M.C.; Longati, P.; Comoglio, P.M. Cross-talk between the proto-oncogenes Met and Ron. Oncogene, 2000, 19(27), 3041-3049.
65. Corso, S.; Comoglio, P.M.; Giordano, S. Cancer therapy: can the challenge be MET? Trends Mol. Med., 2005, 11(6), 284-292.
66. Guo, A.; Villen, J.; Kornhauser, J.; Lee, K.A.; Stokes, M.P.; Rikova, K.; Possemato, A.; Nardone, J.; Innocenti, G.; Wetzel, R.; Wang, Y.; MacNeill, J.; Mitchell, J.; Gygi, S.P.; Rush, J.; Polakiewicz, R.D.; Comb, M.J. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. USA, 2008, 105(2), 692-697.
67. Peace, B.E.; Hill, K.J.; Degen, S.J.; Waltz, S.E. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp. Cell Res., 2003, 289(2), 317-325.
68. Danilkovitch-Miagkova, A.; Angeloni, D.; Skeel, A.; Donley, S.; Lerman, M.; Leonard, E.J. Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J. Biol. Chem., 2000, 275(20), 14783-14786.
69. Danilkovitch-Miagkova, A.; Leonard, E.J. Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors. Histol. Histopathol., 2001, 16(2), 623-631.
70. Maggiora, P.; Lorenzato, A.; Fracchioli, S.; Costa, B.; Castagnaro, M.; Arisio, R.; Katsaros, D.; Massobrio, M.; Comoglio, P.M.; Flavia Di Renzo, M. The RON and MET oncogenes are coexpressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp. Cell Res., 2003, 288(2), 382-389.
71. Burgess, T.; Coxon, A.; Meyer, S.; Sun, J.; Rex, K.; Tsuruda, T.; Chen, Q.; Ho, S.Y.; Li, L.; Kaufman, S.; McDorman, K.; Cattley, R.C.; Sun, J.; Elliott, G.; Zhang, K.; Feng, X.; Jia, X.C.; Green, L.; Radinsky, R.; Kendall, R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/ c-Met-dependent human tumors. Cancer Res., 2006, 66(3), 1721-1729.
72. Jun, H.T.; Sun, J.; Rex, K.; Radinsky, R.; Kendall, R.; Coxon, A.; Burgess, T.L. AMG 102, a fully human anti-hepatocyte growth factor/ scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin. Cancer Res., 2007, 13(22 Pt 1), 6735-6742.
73. Kim, K.J.; Wang, L.; Su, Y.C.; Gillespie, G.Y.; Salhotra, A.; Lal, B.; Laterra, J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res., 2006, 12(4), 1292-1298.
74. Jin, H.; Yang, R.; Zheng, Z.; Romero, M.; Ross, J.; Bou-Reslan, H.; Carano, R.A.; Kasman, I.; Mai, E.; Young, J.; Zha, J.; Zhang, Z.; Ross, S.; Schwall, R.; Colbern, G.; Merchant, M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res., 2008, 68(11), 4360-4368.
75. Sattler, M.; Pride, Y.B.; Ma, P.; Gramlich, J.L.; Chu, S.C.; Quinnan, L.A.; Shirazian, S.; Liang, C.; Podar, K.; Christensen, J.G.; Salgia, R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res., 2003, 63(17), 5462-5469.
76. Christensen, J.G.; Schreck, R.; Burrows, J.; Kuruganti, P.; Chan, E.; Le, P.; Chen, J.; Wang, X.; Ruslim, L.; Blake, R.; Lipson, K.E.; Ramphal, J.; Do, S.; Cui, J.J.; Cherrington, J.M.; Mendel, D.B. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res., 2003, 63(21), 7345-7355.
77. Zhang, Y.; Kaplan-Lefko, P.J.; Rex, K.; Yang, Y.; Moriguchi, J.; Osgood, T.; Mattson, B.; Coxon, A.; Reese, M.; Kim, T.S.; Lin, J.; Chen, A.; Burgess, T.L.; Dussault, I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res., 2008, 68(16), 6680-6687.
78. Berthou, S.; Aebersold, D.M.; Schmidt, L.S.; Stroka, D.; Heigl, C.; Streit, B.; Stalder, D.; Gruber, G.; Liang, C.; Howlett, A.R.; Candinas, D.; Greiner, R.H.; Lipson, K.E.; Zimmer, Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene, 2004, 23(31), 5387-5393.
79. Bellon, S.F.; Kaplan-Lefko, P.; Yang, Y.; Zhang, Y.; Moriguchi, J.; Rex, K.; Johnson, C.W.; Rose, P.E.; Long, A.M.; O'Connor, A.B.; Gu, Y.; Coxon, A.; Kim, T.S.; Tasker, A.; Burgess, T.L.; Dussault, I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J. Biol. Chem., 2008, 283(5), 2675-2683.
80. Puri, N.; Khramtsov, A.; Ahmed, S.; Nallasura, V.; Hetzel, J.T.; Jagadeeswaran, R.; Karczmar, G.; Salgia, R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res., 2007, 67(8), 3529-3534.
81. Zou, H.Y.; Li, Q.; Lee, J.H.; Arango, M.E.; McDonnell, S.R.; Yamazaki, S.; Koudriakova, T.B.; Alton, G.; Cui, J.J.; Kung, P.P.; Nambu, M.D.; Los, G.; Bender, S.L.; Mroczkowski, B.; Christensen, J.G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through anti-proliferative and antiangiogenic mechanisms. Cancer Res., 2007, 67(9), 4408-4417.
82. Christensen, J.G.; Zou, H.Y.; Arango, M.E.; Li, Q.; Lee, J.H.; McDonnell, S.R.; Yamazaki, S.; Alton, G.R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther., 2007, 6(12 Pt 1), 3314-3322.
83. Wood, E.R.; Truesdale, A.T.; McDonald, O.B.; Yuan, D.; Hassell, A.; Dickerson, S.H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K.J.; Rusnak, D.W.; Gilmer, T.M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res., 2004, 64(18), 6652-6659.
84. Claridge, S.; Raeppel, F.; Granger, M.C.; Bernstein, N.; Saavedra, O.; Zhan, L.; Llewellyn, D.; Wahhab, A.; Deziel, R.; Rahil, J.; Beaulieu, N.; Nguyen, H.; Dupont, I.; Barsalou, A.; Beaulieu, C.; Chute, I.; Gravel, S.; Robert, M.F.; Lefebvre, S.; Dubay, M.; Pascal, R.; Gillespie, J.; Jin, Z.; Wang, J.; Besterman, J.M.; MacLeod, A.R.; Vaisburg, A. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg. Med. Chem. Lett., 2008, 18(9), 2793-2798.
85. Cui, J. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert. Opin. Ther. Pat., 2007, 17(9), 1035-1045.
86. Albrecht, B.K.; Harmange, J.C.; Bauer, D.; Berry, L.; Bode, C.; Boezio, A.A.; Chen, A.; Choquette, D.; Dussault, I.; Fridrich, C.; Hirai, S.; Hoffman, D.; Larrow, J.F.; Kaplan-Lefko, P.; Lin, J.; Lohman, J.; Long, A.M.; Moriguchi, J.; O'Connor, A.; Potashman, M.H.; Reese, M.; Rex, K.; Siegmund, A.; Shah, K.; Shimanovich, R.; Springer, S.K.; Teffera, Y.; Yang, Y.; Zhang, Y.; Bellon, S.F. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J. Med. Chem., 2008, 51(10), 2879-2882.
87. Schroeder, G.M.; Chen, X.T.; Williams, D.K.; Nirschl, D.S.; Cai, Z.W.; Wei, D.; Tokarski, J.S.; An, Y.; Sack, J.; Chen, Z.; Huynh, T.; Vaccaro, W.; Poss, M.; Wautlet, B.; Gullo-Brown, J.; Kellar, K.; Manne, V.; Hunt, J.T.; Wong, T.W.; Lombardo, L.J.; Fargnoli, J.; Borzilleri, R.M. Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase. Bioorg. Med. Chem. Lett., 2008, 18(6), 1945-1951.